Menopausal hormone therapy in breast cancer survivors: A review
Highlights The use of menopausal hormone therapy by breast cancer survivors is controversial. Non-hormonal therapies are the first-line option but may not adequately control symptoms. Low-dose vaginal estrogen appears effective with minimal systemic absorption. The use of systemic menopausal hormone therapy remains debated due to heterogeneous and limited safety data. Management should be individualized, with multidisciplinary shared decision-making.
Authors
- Holly J. Pederson (ORCID: https://orcid.org/0000-0003-4325-8370)
- Lauren M. Granat (ORCID: https://orcid.org/0000-0001-8362-5492)
- Megan Kruse (ORCID: https://orcid.org/0000-0002-0536-9005)
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
Publication Details
- Journal
- Maturitas
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.maturitas.2026.108929
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00